<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 21 Mar 2021 09:56:36 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>生物分析专栏 | 治疗性蛋白药物免疫原性分析</title><link>https://mp.weixin.qq.com/s/7BBF7WZToeOQ3YrVcPB6bA</link><description></description><content:encoded><![CDATA[生物分析专栏 | 治疗性蛋白药物免疫原性分析]]></content:encoded><pubDate>Sun, 21 Mar 2021 08:34:27 +0800</pubDate></item><item><title>招聘 | 选择魔方，选择成长</title><link>https://mp.weixin.qq.com/s/SpLFIPlKRuEVJCYVNUEdQw</link><description></description><content:encoded><![CDATA[招聘 | 选择魔方，选择成长]]></content:encoded><pubDate>Sun, 21 Mar 2021 08:34:27 +0800</pubDate></item><item><title>CDMO整合加速</title><link>https://mp.weixin.qq.com/s/ZGEF_k8LnWfGp6nq0cS2hA</link><description></description><content:encoded><![CDATA[CDMO整合加速]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>【聚焦PROTAC】118个在研热门靶点</title><link>https://mp.weixin.qq.com/s/IvdkR-VOir31YJ7D0EQv9g</link><description></description><content:encoded><![CDATA[【聚焦PROTAC】118个在研热门靶点]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>再鼎医药「瑞派替尼片」即将获批上市</title><link>https://mp.weixin.qq.com/s/wftqv-ks5QZcAUu6kR8-6A</link><description></description><content:encoded><![CDATA[再鼎医药「瑞派替尼片」即将获批上市]]></content:encoded><pubDate>Sat, 20 Mar 2021 08:46:56 +0800</pubDate></item><item><title>靶向c-Met：特泊替尼 vs 卡马替尼 vs 赛沃替尼</title><link>https://mp.weixin.qq.com/s/QT-kHFF8hQ9rh5Q82qBJPQ</link><description></description><content:encoded><![CDATA[靶向c-Met：特泊替尼 vs 卡马替尼 vs 赛沃替尼]]></content:encoded><pubDate>Fri, 19 Mar 2021 08:00:33 +0800</pubDate></item><item><title>Science子刊：关键靶点Prosaposin浮出水面，动脉粥样硬化或迎来RNAi疗法！</title><link>https://mp.weixin.qq.com/s/sMvAA5c3C-VPjAYAOMg09Q</link><description></description><content:encoded><![CDATA[Science子刊：关键靶点Prosaposin浮出水面，动脉粥样硬化或迎来RNAi疗法！]]></content:encoded><pubDate>Fri, 19 Mar 2021 08:00:33 +0800</pubDate></item><item><title>远大医药2020年业绩：净利润增长56%，科技创新布局厚积薄发</title><link>https://mp.weixin.qq.com/s/d26eXVyG10mDcuMib0MjEA</link><description></description><content:encoded><![CDATA[远大医药2020年业绩：净利润增长56%，科技创新布局厚积薄发]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局</title><link>https://mp.weixin.qq.com/s/VRCgsHxhp0ZN695HE5IhlA</link><description></description><content:encoded><![CDATA[Tecentriq vs Keytruda：三阴乳腺癌竞争白热化，一图尽览核心临床布局]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>PD-1抗体“新搭档”：融合IL-21，抗肿瘤疗效大大提升 | Nature子刊</title><link>https://mp.weixin.qq.com/s/TLUS4hQyF-K7Hk8sSHChLQ</link><description></description><content:encoded><![CDATA[PD-1抗体“新搭档”：融合IL-21，抗肿瘤疗效大大提升 | Nature子刊]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>保诺—桑迪亚搭建PROTAC研发平台，助力“不可成药性”为“高成药性”</title><link>https://mp.weixin.qq.com/s/1pY5a5JB3OqLlT5avF4p4Q</link><description></description><content:encoded><![CDATA[保诺—桑迪亚搭建PROTAC研发平台，助力“不可成药性”为“高成药性”]]></content:encoded><pubDate>Thu, 18 Mar 2021 08:01:25 +0800</pubDate></item><item><title>首药控股科创板IPO获受理！Pre-IPO估值50亿</title><link>https://mp.weixin.qq.com/s/E08xXsC_zWEC3vfT4Ir_eA</link><description></description><content:encoded><![CDATA[首药控股科创板IPO获受理！Pre-IPO估值50亿]]></content:encoded><pubDate>Wed, 17 Mar 2021 07:43:56 +0800</pubDate></item><item><title>泰诺麦博TNM002单抗成功获美国FDA批准IND</title><link>https://mp.weixin.qq.com/s/Qd1nKvh2YMGXkIChnbS-BA</link><description></description><content:encoded><![CDATA[泰诺麦博TNM002单抗成功获美国FDA批准IND]]></content:encoded><pubDate>Wed, 17 Mar 2021 07:43:56 +0800</pubDate></item><item><title>拨云见日！首个阿尔茨海默症“声光”疗法II期结果积极：显著改善记忆、认知、脑萎缩</title><link>https://mp.weixin.qq.com/s/4FBQ6YSHhbCLmHhnibN5Vw</link><description></description><content:encoded><![CDATA[拨云见日！首个阿尔茨海默症“声光”疗法II期结果积极：显著改善记忆、认知、脑萎缩]]></content:encoded><pubDate>Wed, 17 Mar 2021 07:43:56 +0800</pubDate></item><item><title>百济神州闫小军：巧妙制定注册策略，为新药开发降成本、提速度</title><link>https://mp.weixin.qq.com/s/bdF2myJb2FFCOfA-y3u3uQ</link><description></description><content:encoded><![CDATA[百济神州闫小军：巧妙制定注册策略，为新药开发降成本、提速度]]></content:encoded><pubDate>Tue, 16 Mar 2021 07:46:55 +0800</pubDate></item><item><title>新型RNAi药物来了！有效穿透血脑屏障，促进肿瘤细胞死亡 | Science子刊突破成果</title><link>https://mp.weixin.qq.com/s/O1MEmQZXUi_90WcPR8kz5w</link><description></description><content:encoded><![CDATA[新型RNAi药物来了！有效穿透血脑屏障，促进肿瘤细胞死亡 | Science子刊突破成果]]></content:encoded><pubDate>Tue, 16 Mar 2021 07:46:55 +0800</pubDate></item><item><title>外泌体，掀起药物研发下一波热潮</title><link>https://mp.weixin.qq.com/s/AvpZmpFag-ek_Z5cLQPuCw</link><description></description><content:encoded><![CDATA[外泌体，掀起药物研发下一波热潮]]></content:encoded><pubDate>Mon, 15 Mar 2021 08:30:26 +0800</pubDate></item><item><title>国际权威肿瘤学家毛力出任丽珠生物CEO；朱凌宇博士出任首席商务官</title><link>https://mp.weixin.qq.com/s/8U_5zQYR-1n0al6_3uYuFg</link><description></description><content:encoded><![CDATA[国际权威肿瘤学家毛力出任丽珠生物CEO；朱凌宇博士出任首席商务官]]></content:encoded><pubDate>Mon, 15 Mar 2021 08:30:26 +0800</pubDate></item><item><title>2020肿瘤新药数据卡——氯化镭[223Ra]</title><link>https://mp.weixin.qq.com/s/OC8NuJONR6sIAuxDW96yLw</link><description></description><content:encoded><![CDATA[2020肿瘤新药数据卡——氯化镭[223Ra]]]></content:encoded><pubDate>Mon, 15 Mar 2021 08:30:26 +0800</pubDate></item><item><title>德琪医药任命Minyoung Kim为德琪韩国总经理</title><link>https://mp.weixin.qq.com/s/J02lgByk1lHmi663R1R4vA</link><description></description><content:encoded><![CDATA[德琪医药任命Minyoung Kim为德琪韩国总经理]]></content:encoded><pubDate>Mon, 15 Mar 2021 08:30:26 +0800</pubDate></item></channel></rss>